Bruker (BRKR)
(Delayed Data from NSDQ)
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Zacks News
Here's Why Investors Should Buy Bruker (BRKR) Stock Now
by Zacks Equity Research
The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.
Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG
by Zacks Equity Research
Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.
Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter
by Zacks Equity Research
Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.
Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities
by Zacks Equity Research
Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.
Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems
by Zacks Equity Research
Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.
Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal
by Zacks Equity Research
Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.
Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Bruker (BRKR) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bruker (BRKR) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 4.17% and 5.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 8.11% and 0.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.
Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023
by Zacks Equity Research
Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.
Bruker (BRKR) Launches the SciY Platform of Software Solutions
by Zacks Equity Research
Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.
Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
by Zacks Equity Research
Bruker's (BRKR) new D6 PHASER platform is to be used for material analysis and advanced research.
Bruker (BRKR) Launches ENRICH-iST Kits and Novel Workflow
by Zacks Equity Research
Bruker's (BRKR) ENRICH-iST kit is ready to use right out of the box. The workflow is simple to understand and fully automatable.
Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan
by Zacks Equity Research
Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.
Bruker's (BRKR) Latest Workflows to Aid Applied Markets
by Zacks Equity Research
Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.
Bruker's (BRKR) New Buyout to Advance Digital Transformation
by Zacks Equity Research
Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.
Bruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook
by Zacks Equity Research
Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.
Bruker (BRKR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 16.36% and 7.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for TE Connectivity (TEL) in Q2 Earnings?
by Zacks Equity Research
TE Connectivity's (TEL) fiscal second-quarter results are expected to reflect strength in the Industrial segment. However, weak Communication and Transportation segments might have been concerns.
What to Expect Ahead of Amazon's (AMZN) Q1 Earnings Release?
by Zacks Equity Research
Amazon's (AMZN) first-quarter results are expected to reflect strength across its Prime and cloud businesses and the smart device portfolio amid rising inflationary pressure.